Case study: Discovery of inhibitors of the MDM2–p53 protein-protein interaction

Methods in Molecular Biology

Volumn 1278, Issue , 2015, Pages 567-585

  Liu, Liu ^a   Bernard, Denzil ^a   Wang, Shaomeng ^a  

^a NONE

Author keywords

Cancer therapy; High throughput screening; MDM2; p53; Protein protein interaction; Virtual screening

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53;

ANALYTIC METHOD; ARTICLE; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SURFACE PLASMON RESONANCE;

EID: 84927926193     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2425-7_38     Document Type: Article

References (73)

1. Fry DC, Vassilev LT (2005) Targeting proteinprotein interactions for cancer therapy. J Mol Med 83: 955-963.
2. Murray JK, Gellman SH (2007) Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers 88: 657-686.
3. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22: 9030-9040.
4. Hainaut P, HollsteinM(2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137.
5. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310.
6. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
7. Feki A, Irminger-Finger I (2004) Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52: 103-116.
8. Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
9. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10: 1565-1569.
10. Fakharzadeh SS, Rosenblum-Vos L, MurphyM et al (1993) Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15: 283-290.
11. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
12. Linzer DI, Levine AJ (1979)Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
13. DeLeo AB, Jay G, Appella E et al (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76: 2420-2424.
14. Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
15. Oliner JD, Kinzler KW, Meltzer PS et al (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
16. Zhou M, Gu L, Abshire TC et al (2000) Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14: 61-67.
17. Rayburn E, Zhang R, He J et al (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5: 27-41.
18. Momand J, Jung D, Wilczynski S et al (1998) The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459.
19. Gunther T, Schneider-Stock R, Hackel C et al (2000) Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 13: 621-626.
20. Bond GL, HuW, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
21. Jones SN, Roe AE, Donehower LA et al (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
22. de Oca M, Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
23. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31.
24. Chene P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
25. Shangary S, Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324.
26. Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107.
27. Juven-Gershon T, Oren M (1999) Mdm2: the ups and downs. Mol Med 5: 71-83.
28. Wu X, Bayle JH, Olson D et al (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132.
29. Kussie PH, Gorina S, Marechal V et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
30. Millard M, Pathania D, Grande F et al (2011) Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr Pharm Des 17: 536-559.
31. Zhan C, Lu W (2011) Peptide activators of the p53 tumor suppressor. Curr Pharm Des 17: 603-609.
32. Zak K, Pecak A, Rys B et al (2013) Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat 23: 425-448.
33. Vassilev LT (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3: 419-421.
34. Ding K, Lu Y, Nikolovska-Coleska Z et al (2006) Structure-based design of spirooxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49: 3432-3435.
35. Ding K, Lu Y, Nikolovska-Coleska Z et al (2005) Structure-based design of potent nonpeptide MDM2 inhibitors. J Am Chem Soc 127: 10130-10131.
36. Grasberger BL, Lu T, Schubert C et al (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909-912.
37. Parks DJ, Lafrance LV, Calvo RR et al (2005) 1, 4-Benzodiazepine-2, 5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg Med Chem Lett 15: 765-770.
38. Koblish HK, Zhao S, Franks CF et al (2006) Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 5: 160-169.
39. Allen JG, Bourbeau MP, Wohlhieter GE et al (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem 52: 7044-7053.
40. Rew Y, Sun D, Gonzalez-Lopez De Turiso F et al (2012) Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem 55: 4936-4954.
41. Graves B, Thompson T, Xia M et al (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 109: 11788-11793.
42. Miyazaki M, Kawato H, Naito H et al (2012) Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships. Bioorg Med Chem Lett 22: 6338-6342.
43. Yin H, Lee GI, Park HS et al (2005) Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl 44: 2704-2707.
44. Chen L, Yin H, Farooqi B et al (2005) p53 alpha-helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol Cancer Ther 4: 1019-1025.
45. Lu Y, Nikolovska-Coleska Z, Fang X et al (2006) Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 49: 3759-3762.
46. Galatin PS, Abraham DJ (2004) A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J Med Chem 47: 4163-4165.
47. Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 303: 844-848.
48. Schasfoort RBM, Tudos AJ (2008) Handbook of surface plasmon resonance. Royal Society of Chemistry Publishing, Cambridge, UK.
49. Fry DC, Graves B, Vassilev LT (2005) Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. Methods Enzymol 399: 622-633.
50. Vu B, Wovkulich P, Pizzolato G et al (2013) Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett 4: 466-469.
51. Ericsson UB, Hallberg BM, Detitta GT et al (2006) Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem 357: 289-298.
52. Lo MC, Aulabaugh A, Jin G et al (2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 332: 153-159.
53. Shangary S, Qin D, McEachern D et al (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad SciUS A 105: 3933-3938.
54. Yu S, Qin D, Shangary S et al (2009) Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 52: 7970-7973.
55. Garcia-Echeverria C, Chene P, Blommers MJ et al (2000) Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 43: 3205-3208.
56. Nikolovska-Coleska Z, Wang R, Fang X et al (2004) Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 332: 261-273.
57. Huang X (2003) Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 8: 34-38.
58. Kenakin TP (1993) Pharmacologic analysis of drug-receptor interaction, 2nd edn. Raven, New York.
59. Munson PJ, Rodbard D (1988) An exact correction to the "Cheng-Prusoff" correction. J Recept Res 8: 533-546.
60. Zhang R, Mayhood T, Lipari P et al (2004) Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Anal Biochem 331: 138-146.
61. Kutzki O, Park HS, Ernst JT et al (2002) Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 124: 11838-11839.
62. Boettcher A, Buschmann N, Furet P, et al. (2008) 3-imidazolyl-indoles for the treatment of proliferative diseases. US Patent WO 2008119741.
63. Go ML, Wu X, Liu XL (2005) Chalcones: an update on cytotoxic and chemoprotective properties. Curr Med Chem 12: 481-499.
64. Stoll R, Renner C, Hansen S et al (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40: 336-344.
65. Uoto K, Kawato H, Sugimoto Y, et al. (2009) Imidazothiazole derivative having 4, 7-diazaspiro[2. 5]octane ring structure. US Patent WO/2009/151069.
66. Michelsen K, Jordan JB, Lewis J et al (2012) Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J Am Chem Soc 134: 17059-17067.
67. Lin J, Chen J, Elenbaas B et al (1994) Several hydrophobic amino acids in the p53 aminoterminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8: 1235-1246.
68. Bottger V, Bottger A, Howard SF et al (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141-2147.
69. Bowman AL, Nikolovska-Coleska Z, Zhong H et al (2007) Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J Am Chem Soc 129: 12809-12814.
70. Jones G, Willett P, Glen RC et al (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
71. Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
72. Eldridge MD, Murray CW, Auton TR et al (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11: 425-445.
73. Wang R, Lai L, Wang W (2002) Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des 16: 11-26.